Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
Inhibitors of HBV replication of formula (I) including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein X, R 1 to R 7 have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HBV inhibitors, in HBV therapy.
1. A compound of Formula (I)
or a stereoisomer or tautomeric form thereof, wherein:
is
each of Ra, Rb, Rc, Rd, Re, Rf and Rg are independently selected from the group consisting of hydrogen and methyl;
Rh is hydrogen;
Ri is hydrogen;
R 1 , R 2 and R 3 are independently selected from the group consisting of hydrogen, fluoro, chloro, bromo, —CHF 2 , —CH 2 F, —CF 3 , —CN and methyl;
R 6 is selected from the group consisting of C 1 -C 6 alkyl and a 3-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N, said C 1 -C 6 alkyl and 3-7 membered saturated ring each optionally substituted with one or more substituents selected from the group consisting of fluoro and C 1 -C 3 alkyl, wherein said C 1 -C 3 alkyl is optionally substituted with one or more substituents selected from the group consisting of fluoro, —CN, and OH;
R 7 is hydrogen;
or a pharmaceutically acceptable salt or a solvate thereof.
2. A compound of Formula (II) according to claim 1
or a stereoisomer or tautomeric form thereof, wherein:
n is 1 or 2;
R 1 , R 2 and R 3 are independently selected from the group consisting of hydrogen, fluoro, chloro, bromo, —CHF 2 , —CH 2 F, —CF 3 , —CN and methyl;
R 4 and R 5 are independently selected from hydrogen or methyl;
R 6 is selected from the group consisting of C 1 -C 6 alkyl and a 3-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N, said C 1 -C 6 alkyl and 3-7 membered saturated ring each optionally substituted with one or more substituents selected from the group consisting of fluoro and C 1 -C 3 alkyl wherein said C 1 -C 3 alkyl is optionally substituted with one or more substituents selected from the group consisting of fluoro, —CN, and OH;
R 7 is hydrogen;
or a pharmaceutically acceptable salt or a solvate thereof.
3. A compound according to claim 1 , wherein R 1 is selected from the group consisting of hydrogen, fluoro, chloro, —CHF 2 , —CN, —CF 3 and methyl.
4. A compound according to claim 1 , wherein at least two of R 1 , R 2 and R 3 are each independently fluoro, chloro or bromo.
5. A compound according to claim 2 , wherein R 4 is methyl.
6. A compound according to claim 1 , wherein R 6 is a 3-7 membered saturated ring optionally containing one oxygen, wherein said 3-7 membered saturated ring is optionally substituted with methyl.
7. A compound according to claim 1 , wherein R 6 is a 4 or 5 membered saturated ring containing one oxygen, wherein said 4 or 5 membered saturated ring is optionally substituted with methyl.
8. A compound according to claim 1 , wherein R 6 is a branched C 1 -C 6 alkyl optionally substituted with one or more fluoro.
9. A compound of Formula (III) according to claim 2
wherein R 1 is not hydrogen.
10. A compound according to claim 1 , wherein the stereochemical configuration of atom (*) is as follows
11. A pharmaceutical composition comprising a compound according to claim 1 , and a pharmaceutically acceptable carrier.
12. A compound according to claim 1 in combination with at least one other anti-HBV agent.
13. A compound according to claim 2 , wherein R 1 is selected from the group consisting of hydrogen, fluoro, chloro, —CHF 2 , —CN, —CF 3 and methyl.
14. A compound selected from the group consisting of:
(S)—N-(3-bromo-4,5-difluorophenyl)-1-(2-oxo-2-(((R)-1,1,1-trifluoropropan-2-yl)amino)acetyl)pyrrolidine-3-carboxamide;
(S)—N-(3-bromo-4,5-difluorophenyl)-1-(2-((3-methyloxetan-3-yl)amino)-2-oxoacetyl)pyrrolidine-3-carboxamide;
(S)—N-(3-bromo-4,5-difluorophenyl)-1-(2-(tert-butylamino)-2-oxoacetyl)pyrrolidine-3-carboxamide;
(3S)—N-(4-Fluoro-3-methylphenyl)-1-{[(1-methylethy)amino](oxo)acetyl}pyrrolidine-3-carboxamide;
(S)-1-(2-(cyclopentylamino)-2-oxoacetyl)-N-(4-fluoro-3-methylphenyl)pyrrolidine-3-carboxamide;
(S)—N-(4-fluoro-3-methylphenyl)-1-(2-(((R)-1-hydroxypropan-2-yl)amino)-2-oxoacetyl)pyrrolidine-3-carboxamide;
(3S)—N-(4-Fluoro-3-methylphenyl)-1-{[(3-methyloxetan-3-yl)amino](oxo)acetyl}pyrrolidine-3-carboxamide;
(3S)—N-(4-Fluoro-3-methylphenyl)-1-[{[(1R)-1-methylpropyl]amino}(oxo)acetyl]pyrrolidine-3-carboxamide;
(3S)—N-(4-Fluoro-3-methylphenyl)-1-{oxo[(3S)-tetrahydrofuran-3-ylamino]acetyl}pyrrolidine-3-carboxamide;
(2S, 3S)—N-(4-Fluoro-3-methylphenyl)-2-methyl-1-{[(3-methyloxetan-3-yl)-amino](oxo)acetyl}pyrrolidine-3-carboxamide;
(S)—N-(3-chloro-4,5-difluorophenyl)-1-(2-oxo-2-(((R)-1,1,1-trifluoropropan-2-yl)amino)acetyl)pyrrolidine-3-carboxamide;
(3S)—N-(4-Fluoro-3-methylphenyl)-1-{[(1-methylethyl)amino](oxo)acetyl}piperidine-3-carboxamide;
(S)—N-(3-chloro-4,5-difluorophenyl)-1-(2-oxo-2-((1-(trifluoromethyl) cyclopropyl)amino)acetyl)pyrrolidine-3-carboxamide;
(S)—N-(4-fluoro-3-(trifluoromethyl)phenyl)-1-(2-oxo-2-(((R)-1,1,1-trifluoropropan-2-yl)amino)acetyl)pyrrolidine-3-carboxamide;
(S)—N-(3-chloro-4,5-difluorophenyl)-1-(2-oxo-2-((1,1, 1-trifluoro-2-methylpropan-2-yl)amino)acetyl)pyrrolidine-3-carboxamide;
N-(4-fluoro-3-methylphenyl)-5-methyl-1-(2-((3-methyloxetan-3-yl)amino)-2-oxoacetyl)pyrrolidine-3-carboxamide;
N-(3-chloro-4,5-difluoro-phenyl)-2,2-dimethyl-1-[2-oxo-2-[[(1R)-2,2,2-trifluoro-1-methyl-ethyl]amino]acetyl]pyrrolidine-3-carboxamide;
(3S)-1-[2-(tert-butylamino)-2-oxo-acetyl]-N-(3-chloro-2,4-difluoro-phenyl)pyrrolidine-3-carboxamide;
(3S)-1-[2-(tert-butylamino)-2-oxo-acetyl]-N-(3-cyano-4-fluorophenyl)pyrrolidine-3-carboxamide;
(3S)—N-(3-chloro-2,4-difluoro-phenyl)-1-[2-oxo-2-[[(1R)-2,2,2-trifluoro-1-methyl-ethyl]amino]acetyl]pyrrolidine-3-carboxamide;
(3S)—N-(3-cyano-4-fluoro-phenyl)-1-[2-oxo-2-[[(1R)-2,2,2-trifluoro-1-methyl-ethyl]amino]acetyl]pyrrolidine-3-carboxamide;
(3S)—N-[4-fluoro-3-(trifluoromethyl)phenyl]-1-[2-(isopropylamino)-2-oxo-acetyl]pyrrolidine-3-carboxamide;
(3S)—N-[4-fluoro-3-(trifluoromethyl)phenyl]-1-[2-[[(1R)-1-methylpropyl]amino]-2-oxo-acetyl]pyrrolidine-3-carboxamide;
(3S)—N-(3-chloro-4-fluoro-phenyl)-1-[2-oxo-2-[[1-(trifluoromethyl)cyclopropyl]amino]acetyl]pyrrolidine-3-carboxamide;
(3S)—N-(3-chloro-4-fluoro-phenyl)-1-[2-oxo-2-[[(1S)-2,2,2-trifluoro-1-methyl-ethyl]amino]acetyl]pyrrolidine-3-carboxamide;
(2S)—N-(3-cyano-4-fluoro-phenyl)-1-[2-(isopropylamino)-2-oxo-acetyl]-2-methyl-pyrrolidine-3-carboxamide;
(2S)—N-(3-chloro-2,4-difluoro-phenyl)-1-[2-(isopropylamino)-2-oxo-acetyl]-2-methyl-pyrrolidine-3-carboxamide;
(2S)—N-(3-chloro-4,5-difluoro-phenyl)-1-[2-(isopropylamino)-2-oxo-acetyl]-2-methyl-pyrrolidine-3-carboxamide;
(3S)—N-[3-(difluoromethyl)-4-fluoro-phenyl]-1-[2-oxo-2-[[(1S)-2,2,2-trifluoro-1-methyl-ethyl]amino]acetyl]pyrrolidine-3-carboxamide;
(3S)—N-[3-(difluoromethyl)-4-fluoro-phenyl]-1-[2-(isopropylamino)-2-oxo-acetyl]pyrrolidine-3-carboxamide;
(3S)-1-[2-oxo-2-[[(1R)-2,2,2-trifluoro-1-methyl-ethyl]amino]acetyl]-N-(3,4,5-trifluorophenyl)pyrrolidine-3-carboxamide;
(2S)—N-(3-chloro-4,5-difluoro-phenyl)-2-methyl-1-[2-oxo-2-[(1R)-(2,2,2-trifluoro-1-methyl-ethyl)amino]acetyl]pyrrolidine-3-carboxamide;
(2S)-2-methyl-1-[2-oxo-2-[[(1R)-2,2,2-trifluoro-1-methyl-ethyl]amino]acetyl]-N-(3,4,5-trifluorophenyl)pyrrolidine-3-carboxamide; and
N-(3-chloro-2,4-difluoro-phenyl)-2-methyl-1-[2-oxo-2-[((1R)-2,2,2-trifluoro-1-methyl-ethyl)amino]acetyl]piperidine-3-carboxamide.
15. A pharmaceutical composition comprising a compound according to claim 14 , and a pharmaceutically acceptable carrier.
16. A method of treating an HBV infection in a subject comprising administering to said subject a therapeutically effective amount of at least one compound of claim 1 , and optionally an additional anti-HBV agent.
17. A method of treating an HBV infection in a subject comprising administering to said subject a therapeutically effective amount of at least one compound of claim 14 , and optionally an additional anti-HBV agent.
18. A compound according to claim 1 in combination with at least one other anti-HBV agent, wherein the at least one other anti-HBV agent is selected from the group consisting of interferon, pegylated interferon, 3TC, adefovir and Toll-like receptor 7 and/or 8 agonists or combinations thereof.
19. A pharmaceutical composition comprising a compound according to claim 1 , a pharmaceutically acceptable carrier and optionally at least one other anti-HBV agent.